ES2373646T3 - Compuestos de 2,4-pirimidindiamina y sus aplicaciones. - Google Patents

Compuestos de 2,4-pirimidindiamina y sus aplicaciones. Download PDF

Info

Publication number
ES2373646T3
ES2373646T3 ES03707654T ES03707654T ES2373646T3 ES 2373646 T3 ES2373646 T3 ES 2373646T3 ES 03707654 T ES03707654 T ES 03707654T ES 03707654 T ES03707654 T ES 03707654T ES 2373646 T3 ES2373646 T3 ES 2373646T3
Authority
ES
Spain
Prior art keywords
group
fluoro
compound
chloro
nrcrc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03707654T
Other languages
English (en)
Spanish (es)
Inventor
Rajinder Singh
Ankush Argade
Donald G. Payan
Susan Molineaux
Sacha J. Holland
Jeffrey Clough
Holger Keim
Somasekhar Bhamidipati
Catherine Sylvain
Hui Li
Alexander B. Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32996332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2373646(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2373646T3 publication Critical patent/ES2373646T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES03707654T 2002-02-01 2003-01-31 Compuestos de 2,4-pirimidindiamina y sus aplicaciones. Expired - Lifetime ES2373646T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35333302P 2002-02-01 2002-02-01
US35326702P 2002-02-01 2002-02-01
US353267P 2002-02-01
US353333P 2002-02-01
US39967302P 2002-07-29 2002-07-29
US399673P 2002-07-29
US43427702P 2002-12-17 2002-12-17
US434277P 2002-12-17
PCT/US2003/003022 WO2003063794A2 (en) 2002-02-01 2003-01-31 2,4-pyrimidinediamine compounds and their uses

Publications (1)

Publication Number Publication Date
ES2373646T3 true ES2373646T3 (es) 2012-02-07

Family

ID=32996332

Family Applications (2)

Application Number Title Priority Date Filing Date
ES03707654T Expired - Lifetime ES2373646T3 (es) 2002-02-01 2003-01-31 Compuestos de 2,4-pirimidindiamina y sus aplicaciones.
ES10011119T Expired - Lifetime ES2440283T3 (es) 2002-02-01 2003-01-31 Compuestos de 2,4-pirimidindiamina y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10011119T Expired - Lifetime ES2440283T3 (es) 2002-02-01 2003-01-31 Compuestos de 2,4-pirimidindiamina y sus usos

Country Status (24)

Country Link
US (41) US7557210B2 (enExample)
EP (2) EP1471915B1 (enExample)
JP (2) JP4658477B2 (enExample)
KR (1) KR101037856B1 (enExample)
CN (2) CN102174024B (enExample)
AT (1) ATE524184T1 (enExample)
AU (2) AU2003208931C1 (enExample)
BR (1) BRPI0307355C1 (enExample)
CA (1) CA2474277C (enExample)
CY (1) CY1112516T1 (enExample)
DK (2) DK2281563T3 (enExample)
ES (2) ES2373646T3 (enExample)
HR (1) HRP20040684B1 (enExample)
IL (1) IL221381A (enExample)
MX (2) MXPA04007386A (enExample)
NO (1) NO328071B1 (enExample)
NZ (1) NZ534361A (enExample)
PL (1) PL214988B1 (enExample)
PT (2) PT1471915E (enExample)
RS (2) RS53367B (enExample)
SG (1) SG167664A1 (enExample)
SI (2) SI1471915T1 (enExample)
TW (1) TWI329105B (enExample)
WO (1) WO2003063794A2 (enExample)

Families Citing this family (383)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1472233A1 (en) * 2002-02-08 2004-11-03 SmithKline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP2005529954A (ja) * 2002-06-17 2005-10-06 スミスクライン ビーチャム コーポレーション 化学プロセス
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
EP2316459B1 (en) * 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ATE458731T1 (de) 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040242613A1 (en) * 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2004074244A2 (en) * 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE602004028841D1 (de) 2003-07-25 2010-10-07 Centre Nat Rech Scient Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
RS53109B (sr) * 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
PL2287156T3 (pl) * 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP4745244B2 (ja) 2003-11-05 2011-08-10 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒアゴニストとしてのフェニル誘導体
BRPI0416519A (pt) * 2003-11-14 2007-03-06 Ashland Licensing & Intellectu composição oligomérica lìquida, produto polimerizado curado, método para fabricar e para usar uma composição oligomérica lìquida, e, substrato
EP1749827A4 (en) * 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
JP2007537235A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
WO2006004776A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1786783A1 (en) * 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
JP2008512429A (ja) * 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
EP1796679A1 (en) * 2004-09-10 2007-06-20 Altana Pharma AG Ciclesonide and syk inhibitor combination and methods of use thereof
AU2005284904A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
AU2005289426A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
WO2006035069A1 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ES2380550T3 (es) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7555655B2 (en) * 2004-12-22 2009-06-30 5th Fleet, L.L.C. Apparatus, system, and method for generating and authenticating a computer password
NZ555947A (en) * 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) * 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
WO2006135915A2 (en) * 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
DE602005000514T2 (de) * 2005-06-17 2007-10-25 Magneti Marelli Powertrain S.P.A. Brennstoffeinspritzventil
TW200740805A (en) * 2005-07-15 2007-11-01 Glaxo Group Ltd Novel compounds
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
MX2008002731A (es) 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
US20090124645A1 (en) * 2005-10-14 2009-05-14 Neurosearch A/S Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EP1959961A2 (en) 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
JP2007186507A (ja) * 2005-12-15 2007-07-26 Nippon Nohyaku Co Ltd フタルアミド誘導体及び農園芸用殺虫剤並びにその使用方法
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
KR101060051B1 (ko) * 2005-12-21 2011-08-29 화이자 프로덕츠 인크. 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체
WO2007085540A1 (en) * 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
KR101411695B1 (ko) * 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
JP2009544592A (ja) * 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP5161233B2 (ja) 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
NZ576425A (en) 2006-10-23 2012-04-27 Cephalon Inc Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
WO2008105968A1 (en) * 2006-11-03 2008-09-04 Smithkline Beecham Corporation Novel seh inhibitors and their use
EP2420505A1 (en) * 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
KR20090103897A (ko) 2006-12-28 2009-10-01 다이쇼 세이야꾸 가부시끼가이샤 피라졸로피리미딘 화합물
EA020749B1 (ru) 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CA2684470C (en) 2007-04-16 2016-02-09 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
KR20120120453A (ko) * 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JP5460600B2 (ja) * 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
JP5411867B2 (ja) * 2007-10-11 2014-02-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
EP2217068A4 (en) * 2007-10-11 2011-09-14 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
NZ584471A (en) * 2007-10-11 2012-01-12 Glaxosmithkline Llc Triazine cyclohexane carboxamide compounds and their use
UA102825C2 (ru) * 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
WO2009073772A1 (en) * 2007-12-06 2009-06-11 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2009097474A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
JP2011510998A (ja) * 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
JP5711537B2 (ja) * 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102066340B (zh) * 2008-04-16 2014-05-14 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
JP2011524398A (ja) 2008-06-16 2011-09-01 エフ．ホフマン−ラ ロシュ アーゲー オレキシニン受容体アンタゴニストとしてのヘテロ芳香族モノアミド
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2344476B1 (en) 2008-09-23 2015-04-29 Rigel Pharmaceuticals, Inc. Tricyclic carbamate jak inhibitors
WO2010038081A2 (en) * 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US8278299B2 (en) 2008-12-30 2012-10-02 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
EP2387572B1 (en) * 2009-01-15 2015-09-16 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
JP5781943B2 (ja) 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
SG172885A1 (en) 2009-01-23 2011-08-29 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
US20110015155A1 (en) 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
WO2011017178A1 (en) * 2009-07-28 2011-02-10 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20120197019A1 (en) * 2009-10-23 2012-08-02 Dharmesh Surendra Bhanushali Compositions and processes
US8389515B2 (en) * 2009-11-20 2013-03-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs and their uses
JP5802677B2 (ja) 2009-12-01 2015-10-28 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
WO2011075560A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
EP2513098B1 (en) 2009-12-17 2016-11-09 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
AT509266B1 (de) * 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
MX2012011821A (es) * 2010-04-12 2012-11-30 Supernus Pharmaceuticals Inc Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
JP6067550B2 (ja) 2010-04-13 2017-01-25 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
JP6035238B2 (ja) 2010-07-21 2016-11-30 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
EP2598500B1 (en) 2010-07-28 2021-05-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2617763T3 (es) 2010-08-10 2017-06-19 Celgene Avilomics Research, Inc. Sal de besilato de un inhibidor de BTK
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES2746134T3 (es) 2010-11-10 2020-03-04 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de LRRK2
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
US20140128276A1 (en) * 2011-01-13 2014-05-08 Oklahoma Medical Research Foundation Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
US9249124B2 (en) * 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
UA120740C2 (uk) 2011-04-22 2020-02-10 Сігнал Фармасьютікалз, Елелсі Заміщені діамінокарбоксамідні і діамінокарбонітрильні похідні піримідинів, їх композиції і способи лікування з їх допомогою
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
AU2012288632B2 (en) 2011-07-28 2017-08-17 Rigel Pharmaceuticals, Inc. New (trimethoxyphenylamino)pyrimidinyl formulations
RS56342B1 (sr) * 2011-09-02 2017-12-29 Purdue Pharma Lp Pirimidini kao blokatori natrijumskog kanala
UY34314A (es) 2011-09-16 2013-04-30 Fovea Pharmaceuticals Derivados de anilina, su preparación y su aplicación terapéutica.
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US20130102596A1 (en) 2011-10-21 2013-04-25 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2856301C (en) 2011-11-23 2020-10-06 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
US20150216955A1 (en) 2012-03-23 2015-08-06 The University Of Queensland Immunomodulatory agent and uses therefor
JP6113828B2 (ja) * 2012-04-04 2017-04-12 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
CA2871926A1 (en) 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
CA2892677A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2014209263B2 (en) 2013-01-25 2018-11-01 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10202356B2 (en) * 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
CA2904610A1 (en) 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US10150742B2 (en) * 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
EP2988749B1 (en) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3013823B1 (en) * 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof
US9850216B2 (en) 2013-08-06 2017-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
CA2940666C (en) 2014-02-28 2022-08-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
MX2016012574A (es) 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
CN106715456B (zh) 2014-08-12 2023-08-29 莫纳什大学 定向淋巴的前药
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
JP6649540B2 (ja) 2014-10-14 2020-02-19 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換されたヘテロアリール化合物および使用方法
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
CA3210612A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
CN107683139A (zh) 2015-05-29 2018-02-09 博尔托拉制药公司 用于治疗b细胞恶性肿瘤的赛度替尼
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017007987A1 (en) * 2015-07-09 2017-01-12 Merck Patent Gmbh Pyrimidine derivatives as btk inhibitors and uses thereof
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3347340A4 (en) 2015-09-08 2019-01-23 Monash University LYMPHENLEITUNGSPRODRUGS
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
RS64114B1 (sr) 2015-10-23 2023-04-28 Navitor Pharm Inc Modulatori interakcije sestrin-gator2 i nјihova upotreba
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
WO2017096303A2 (en) 2015-12-04 2017-06-08 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
CN105646371B (zh) * 2016-01-19 2019-10-01 浙江大学 含异羟肟酸片段的2,4-二芳胺基嘧啶类衍生物及制备和应用
WO2017156165A1 (en) 2016-03-09 2017-09-14 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
TWI825663B (zh) 2016-10-14 2023-12-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US10414727B2 (en) 2016-11-08 2019-09-17 Navitor Pharmaceuticals, Inc. Phenyl amino piperidine mTORC inhibitors and uses thereof
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
CN108341835B (zh) * 2017-01-22 2021-01-15 正大天晴药业集团股份有限公司 用作酪氨酸激酶抑制剂的含硼化合物
JP7160824B2 (ja) 2017-03-08 2022-10-25 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤、使用およびその製造のための方法
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
EP4556069A3 (en) 2017-04-26 2025-08-13 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN111217797B (zh) * 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
WO2019023621A1 (en) * 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
AU2018324037A1 (en) 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL322809A (en) 2017-09-22 2025-10-01 Kymera Therapeutics Inc Protein Decomposers and Their Uses
US10052326B1 (en) 2017-10-12 2018-08-21 King Saud University Antihepatotoxic agents
JP2020537678A (ja) 2017-10-19 2020-12-24 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用
JP7167146B2 (ja) 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3746071A4 (en) 2018-01-29 2021-09-01 Merck Patent GmbH GCN2 INHIBITORS AND THEIR USES
CN111918651B (zh) 2018-01-29 2024-01-30 默克专利股份有限公司 Gcn2抑制剂及其用途
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
JP7317032B2 (ja) 2018-02-27 2023-07-28 アルタックス バイオファーマ インコーポレイテッド Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
HRP20220710T1 (hr) 2018-04-24 2022-07-22 Merck Patent Gmbh Antiproliferacijski spojevi i njihova uporaba
TWI884914B (zh) 2018-04-24 2025-06-01 美商維泰克斯製藥公司 喋啶酮化合物及其用途
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
EA202092692A1 (ru) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. Аналоги рапамицина и их применения
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US10487057B1 (en) * 2018-07-05 2019-11-26 Landos Biopharma, Inc. NLRX1 ligands
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
EP3870597A1 (en) 2018-10-23 2021-09-01 BicycleTx Limited Bicyclic peptide ligands and uses thereof
JP7644002B2 (ja) 2018-10-24 2025-03-11 ナビター ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
EP3914357A4 (en) 2019-01-23 2022-10-12 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND THEIR USES
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
US11845724B2 (en) 2019-09-11 2023-12-19 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
BR112022004451A2 (pt) 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
CN114786660A (zh) 2019-11-01 2022-07-22 纳维托制药有限公司 使用mtorc1调节剂的治疗方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
US20220387408A1 (en) 2019-11-12 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021155185A1 (en) * 2020-01-30 2021-08-05 Sumitomo Dainippon Pharma Oncology, Inc. Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
WO2021178488A1 (en) 2020-03-03 2021-09-10 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
PH12022552539A1 (en) * 2020-03-12 2024-01-22 Rigel Pharmaceuticals Inc Method for treatment of covid-19-associated conditions
PH12022552458A1 (en) 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2021392040A1 (en) 2020-12-02 2023-06-29 Ikena Oncology, Inc. Tead inhibitors and uses thereof
MX2023007852A (es) 2020-12-30 2023-07-07 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
CN112920124B (zh) * 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
CA3206499A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CA3206501A1 (en) 2021-02-02 2022-08-11 Shaun Abbott Gpr84 antagonists and uses thereof
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4291187A4 (en) 2021-02-15 2025-01-15 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
JP2024509192A (ja) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023109954A1 (en) 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2023214044A1 (en) 2022-01-31 2024-08-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11478464B1 (en) 2022-02-06 2022-10-25 King Faisal University Method for treating inflammation
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
KR20230155351A (ko) * 2022-05-03 2023-11-10 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20230357125A1 (en) * 2022-05-06 2023-11-09 AMPAC Fine Chemicals Process for Catalytic Reduction of Nitro Compounds to Amines
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
AU2023317740A1 (en) 2022-08-02 2025-03-13 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
EP4565564A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024042361A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
TW202430148A (zh) 2022-11-22 2024-08-01 美商皮克醫療公司 ｅＩＦ４Ｅ抑制劑及其用途
WO2024264017A2 (en) 2023-06-23 2024-12-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease

Family Cites Families (313)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US192301A (en) * 1877-06-19 Improvement in lemon-squeezers
US113398A (en) * 1871-04-04 Improvement in towel-brackets and sponge-holders
US38243A (en) * 1863-04-21 Improvement in flasks for founders
US80858A (en) * 1868-08-11 Ensmore
US3159547A (en) 1963-06-28 1964-12-01 Abbott Lab Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide
US3320256A (en) * 1965-04-09 1967-05-16 Hoffmann La Roche Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5845466A (ja) 1981-09-10 1983-03-16 松下電器産業株式会社 空気調和機
JPS59122899U (ja) 1983-02-08 1984-08-18 松下電器産業株式会社 アイロン
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
JPS6036884U (ja) 1983-08-18 1985-03-14 三洋電機株式会社 ドラム式洗濯機
GR80171B (en) 1983-08-29 1985-01-02 Ciba Geigy Ag N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
HU192875B (en) 1984-10-05 1987-07-28 Richter Gedeon Vegyeszet Process for preparing 2-pyridinethiol derivatives
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
DE3618353A1 (de) * 1986-05-31 1987-12-03 Hoechst Ag Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen
JPS638387A (ja) 1986-06-27 1988-01-14 Yoshitomi Pharmaceut Ind Ltd セフエム化合物
JPH0696592B2 (ja) * 1986-06-30 1994-11-30 株式会社クラレ １７β−ヒドロキシ−１７α−（３−ヒドロキシプロピル）アンドロスタ−４，６−ジエン−３−オンの製造方法
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
EP0285571B1 (de) 1987-04-02 1992-02-05 Ciba-Geigy Ag Reaktivfarbstoffe, deren Herstellung und Verwendung
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
SU1499883A1 (ru) 1987-11-24 1991-10-23 Научно-исследовательский институт фармакологии АМН СССР Дихлоргидрат 2,4-бис-(п-трет-бутиланилино)-5-окси-6-метилпиримидина, обладающий анальгетической и противовоспалительной активностью
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
DE68907483T2 (de) * 1988-04-21 1993-10-21 Leo Pharm Prod Ltd Vitamin d analoge.
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
US5179204A (en) * 1989-09-05 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated N-substituted-4-pyrimidinamines and pyrimidinediamines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
TW224941B (enExample) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5532228A (en) * 1990-02-06 1996-07-02 Schering Aktiengesellschaft Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents
DE4011682A1 (de) * 1990-04-06 1991-10-10 Schering Ag 24-oxa-derivate in der vitamin d-reihe
JPH03127790U (enExample) 1990-04-06 1991-12-24
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
JPH04178385A (ja) 1990-11-09 1992-06-25 Yamanouchi Pharmaceut Co Ltd ジケトピリドピラジン誘導体
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
EP0612729B1 (en) 1991-05-10 1997-04-23 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
US5200400A (en) * 1991-07-12 1993-04-06 New England Deaconess Hospital Corporation Method for inhibiting allograft rejection using photoactivatable nucleotides or nucleosides
CA2074864A1 (en) 1991-07-30 1993-01-31 Carmen Almansa Tetralones with pharmacological activity
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
DE4141746A1 (de) * 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives
US5420184A (en) * 1992-10-14 1995-05-30 Mitsubishi Petrochemical Co., Ltd. Thermoplastic resin composition and process for preparing the same
US5335501A (en) 1992-11-16 1994-08-09 General Electric Company Flow spreading diffuser
TW287160B (enExample) * 1992-12-10 1996-10-01 Hoffmann La Roche
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
KR960704855A (ko) * 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5585381A (en) 1994-06-01 1996-12-17 Kureha Chemical Industry Co., Ltd. Pyrimidine derivatives and pharmaceutical composition
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5733932A (en) 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9516121D0 (en) * 1995-08-05 1995-10-04 Pfizer Ltd Organometallic addition to ketones
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
JP4058129B2 (ja) 1996-03-18 2008-03-05 株式会社資生堂 ピリジン誘導体及び抗潰瘍剤、抗菌剤
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6696448B2 (en) * 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US6004985A (en) 1996-10-09 1999-12-21 Berlex Laboratories, Inc. Thio acid derived monocylic N-heterocyclics as anticoagulants
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9723859D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Compound,composition and use
DE19750701A1 (de) 1997-11-15 1999-05-20 Dystar Textilfarben Gmbh & Co Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren
ATE401312T1 (de) * 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
DE69822514T2 (de) 1997-12-31 2005-03-24 The University Of Kansas, Lawrence Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
US6355683B1 (en) * 1998-09-11 2002-03-12 Ilexus Pty Limited Fc receptor modulators and uses thereof
DE69902634T2 (de) 1998-02-13 2003-04-24 Pharmacia & Upjohn Co., Kalamazoo Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
CA2319493A1 (en) 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP1245567B1 (en) * 1998-03-27 2011-03-02 Janssen Pharmaceutica NV HIV inhibiting pyrimidine derivatives
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
DK1071710T4 (da) * 1998-04-15 2011-12-12 Merck Serono Biodevelopment Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO1999061437A1 (en) 1998-05-22 1999-12-02 Smithkline Beecham Corporation Novel 2-alkyl substituted imidazole compounds
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
EP1105378B1 (en) 1998-08-21 2005-03-30 Parker Hughes Institute Quinazoline derivatives
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
DE19851421A1 (de) 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
CA2350801C (en) * 1998-11-10 2008-05-20 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
JP2002529444A (ja) 1998-11-12 2002-09-10 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式シグナル伝達阻害剤、それを含む組成物とその用途
US6127376A (en) 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
FR2788977B1 (fr) 1999-02-02 2002-04-19 Seb Sa Revetement de matieres thermoplastiques pour epilation
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
SE9901079D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel compounds
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
EP1165522A1 (en) 1999-04-06 2002-01-02 Krenitsky Pharmaceuticals, Inc. Neurotrophic thio substituted pyrimidines
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
KR100820605B1 (ko) * 1999-09-24 2008-04-08 얀센 파마슈티카 엔.브이. 항바이러스 조성물
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
AU1026901A (en) 1999-10-29 2001-05-08 Syngenta Participations Ag Novel herbicides
AU4903201A (en) 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
US6610688B2 (en) * 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
ATE369844T1 (de) 2000-01-24 2007-09-15 Genzyme Corp Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
AU782775B2 (en) * 2000-02-05 2005-08-25 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of ERK
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6608048B2 (en) * 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
EP1282607B1 (en) * 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
SK17342002A3 (sk) 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
DE60118576T2 (de) 2000-08-18 2006-11-02 3M Innovative Properties Co., Saint Paul Fluoro(meth)acrylatecopolymer-beschichtungsmassen
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1330459B1 (en) 2000-10-02 2006-08-02 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
WO2002043735A1 (en) 2000-11-29 2002-06-06 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20020115173A1 (en) 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
CA2432114A1 (en) * 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
DK1343782T3 (da) 2000-12-21 2009-08-24 Smithkline Beecham Corp Pyrimidinaminer som angiogenesemodulatorer
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CN100415744C (zh) 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
BR0207526A (pt) 2001-02-23 2004-03-09 Merck & Co Inc Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
MXPA03010961A (es) * 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ES2274035T3 (es) 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
KR100875380B1 (ko) * 2001-06-23 2008-12-23 아벤티스 파마슈티칼스 인크. 단백질 키나제 억제제로서의 피롤로피리미딘
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US20030139435A1 (en) * 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7070996B2 (en) * 2001-08-31 2006-07-04 Rigel Pharmaceuticals, Inc. Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
US6952284B2 (en) * 2001-08-31 2005-10-04 International Business Machines Corporation Manually operated digital printing device
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
MXPA04002242A (es) 2001-09-10 2005-03-07 Sugen Inc Derivados de 3-(4,5,6,7,-tetrahidroindol-2-ilmetiliden)-2-indolinona como inhibidores de cinasa.
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
ATE438629T1 (de) 2001-11-28 2009-08-15 Btg Int Ltd Mittel, die vorbeugend bzw. heilend bei alzheimer-krankheit wirken, oder inhibitoren der fibrose von amyloiden proteinen, enthaltend stickstoffhaltige heteroarylverbindungen
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
FR2835522B1 (fr) 2002-02-06 2006-04-07 Robert Vachy Preparation pour composes sensibles a l'oxydation et son procede de fabrication
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1472233A1 (en) 2002-02-08 2004-11-03 SmithKline Beecham Corporation Pyrimidine compounds
US7153245B2 (en) * 2002-02-14 2006-12-26 Kellion Corporation Golf exerciser
CA2477505A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
NZ535365A (en) 2002-03-20 2006-07-28 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2003301758A1 (en) 2002-05-06 2004-05-25 Bayer Pharmaceuticals Corporation Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
KR20050013562A (ko) 2002-05-30 2005-02-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 ｃｄｋ2 프로테인 키나아제의 억제제
US20050222186A1 (en) 2002-06-14 2005-10-06 Altana Pharma Ag Substituted diaminopyrimidines
JP2005529954A (ja) 2002-06-17 2005-10-06 スミスクライン ビーチャム コーポレーション 化学プロセス
WO2004002964A1 (ja) 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. ジアミノピリミジンカルボキサミド誘導体
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
AU2003249539A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
US7304071B2 (en) * 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1562911B1 (en) * 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
ES2289349T3 (es) * 2002-11-04 2008-02-01 Vertex Pharmaceuticals Incorporated Derivados de heteroaril-pirimidina como inhibidores de jak.
WO2004041810A1 (en) 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
RS20050380A (sr) 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
CN1747937A (zh) 2003-02-07 2006-03-15 詹森药业有限公司 预防hiv感染的嘧啶衍生物
WO2004074244A2 (en) 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
MXPA05011352A (es) 2003-04-23 2005-11-28 Glaxo Group Ltd Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.
EP1618094B1 (en) 2003-04-30 2007-09-05 The Institutes for Pharmaceutical Discovery, LLC Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
EA011300B1 (ru) 2003-07-16 2009-02-27 Янссен Фармацевтика Н.В. Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
ATE370142T1 (de) 2003-07-16 2007-09-15 Janssen Pharmaceutica Nv Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
US7442698B2 (en) * 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2006528629A (ja) 2003-07-24 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害薬
AU2004261484A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
TW200514776A (en) 2003-08-06 2005-05-01 Vertex Pharma Aminotriazole compounds useful as inhibitors of protein kinases
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
WO2005016344A1 (en) 2003-08-14 2005-02-24 Pfizer Limited Piperazine derivatives for the treatment of hiv infections
PL2287156T3 (pl) 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2538413A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2005027848A2 (en) 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
BRPI0414791A (pt) 2003-09-25 2006-11-21 Janssen Pharmaceutica Nv derivados de purina inibidores da replicação do hiv
EA009941B1 (ru) 2003-10-03 2008-04-28 Пфайзер Инк. Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7235161B2 (en) * 2003-11-19 2007-06-26 Alcoa Inc. Stable anodes including iron oxide and use of such anodes in metal production cells
RU2006122853A (ru) 2003-11-28 2008-01-10 Новартис АГ (CH) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2007514775A (ja) 2003-12-19 2007-06-07 ライジェル ファーマシューティカルズ， インコーポレイテッド １−（２，４−ピリミジンジアミノ）−２−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
ES2424642T3 (es) 2004-02-14 2013-10-07 Irm Llc Compuestos y composiciones como inhibidores de la proteína quinasa
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20060047135A1 (en) 2004-08-30 2006-03-02 Chadwick Scott T Process for preparing chloromethyl di-tert-butylphosphate
EP1786783A1 (en) * 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
WO2006034872A1 (de) 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
EP1817303A2 (en) 2004-10-29 2007-08-15 Rigel Pharmaceuticals, Inc. Substituted pyridines with activity on syk kinase
ES2380550T3 (es) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CA2604551A1 (en) 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
US20060251285A1 (en) 2005-05-05 2006-11-09 Mrs. Yen-Chen Chan [surge-proof damper]
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
WO2006135915A2 (en) * 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
BRPI0613452A2 (pt) 2005-07-11 2011-01-11 Sanofi Aventis derivados de 2,4-dianilino pirimidinas, o respectivo preparo, a tìtulo de medicamentos, composições farmacêuticas e notadamente como inibidores de ikk
DK1913009T3 (da) 2005-07-28 2010-08-16 Intervet Int Bv Nye benzimidazol(thio)carbamater med antiparasitisk virkning samt syntese heraf
US20090114877A1 (en) 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
US20070117775A1 (en) 2005-10-31 2007-05-24 Rigel Pharmaceuticals, Inc. Compositions and Methods For Treating Inflammatory Disorders
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
WO2007076427A2 (en) 2005-12-21 2007-07-05 Konarka Technologies, Inc. Tandem photovoltaic cells
US7962290B1 (en) * 2006-01-09 2011-06-14 Rigel Pharmaceuticals, Inc. Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007085540A1 (en) 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
KR101411695B1 (ko) 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007124589A1 (en) 2006-05-02 2007-11-08 Merck Frosst Canada Ltd. Methods for treating or preventing neoplasias
US7776855B2 (en) 2006-07-27 2010-08-17 Janssen Pharmaceutica N.V. Antimicrobial oxazolidinone prodrugs
JP5161233B2 (ja) 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7834024B2 (en) * 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
MX343517B (es) * 2011-03-10 2016-11-07 Rigel Pharmaceuticals Inc 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.

Also Published As

Publication number Publication date
MX341239B (es) 2016-08-12
NO20043632L (no) 2004-10-26
PL373530A1 (en) 2005-09-05
US8835430B2 (en) 2014-09-16
US8748597B2 (en) 2014-06-10
US20160009661A1 (en) 2016-01-14
JP4658477B2 (ja) 2011-03-23
US7589200B2 (en) 2009-09-15
US10369148B2 (en) 2019-08-06
US9913842B2 (en) 2018-03-13
US20130150349A1 (en) 2013-06-13
HK1154216A1 (en) 2012-04-13
US20070293520A1 (en) 2007-12-20
BRPI0307355C1 (pt) 2021-05-25
US20120045454A1 (en) 2012-02-23
US20140303154A1 (en) 2014-10-09
HRP20040684A2 (hr) 2008-12-31
US20090156622A1 (en) 2009-06-18
US20090082567A1 (en) 2009-03-26
EP2281563B1 (en) 2013-09-18
CY1112516T1 (el) 2015-12-09
US20170081290A1 (en) 2017-03-23
RS54105B1 (sr) 2015-10-30
US20130324524A1 (en) 2013-12-05
US20060135543A1 (en) 2006-06-22
HK1069538A1 (en) 2005-05-27
NO328071B1 (no) 2009-11-23
US20150329532A1 (en) 2015-11-19
US20060058292A1 (en) 2006-03-16
US9018204B1 (en) 2015-04-28
AU2003208931C1 (en) 2009-04-02
US20070293521A1 (en) 2007-12-20
US9540334B2 (en) 2017-01-10
NZ534361A (en) 2008-04-30
US20210267971A1 (en) 2021-09-02
US20050209230A1 (en) 2005-09-22
CA2474277C (en) 2013-09-24
KR20040101216A (ko) 2004-12-02
US20130317216A1 (en) 2013-11-28
BR0307355A (pt) 2006-04-11
US9416112B2 (en) 2016-08-16
WO2003063794A3 (en) 2003-12-04
DK2281563T3 (da) 2014-01-13
KR101037856B1 (ko) 2011-06-01
US7060827B2 (en) 2006-06-13
HRP20040684B1 (hr) 2014-07-04
JP5357116B2 (ja) 2013-12-04
CN1625400B (zh) 2011-04-13
US20140031350A1 (en) 2014-01-30
BRPI0307355B1 (pt) 2018-11-13
CN102174024A (zh) 2011-09-07
US8853397B2 (en) 2014-10-07
US7803939B2 (en) 2010-09-28
US9133133B2 (en) 2015-09-15
US20060035916A1 (en) 2006-02-16
EP1471915A4 (en) 2006-02-15
YU67404A (sh) 2006-08-17
US20150005297A1 (en) 2015-01-01
US7329671B2 (en) 2008-02-12
US20100197918A1 (en) 2010-08-05
PL214988B1 (pl) 2013-10-31
US7485724B2 (en) 2009-02-03
SI2281563T1 (sl) 2014-02-28
TW200307547A (en) 2003-12-16
JP2005516046A (ja) 2005-06-02
US8188276B2 (en) 2012-05-29
US8822685B2 (en) 2014-09-02
US11007193B2 (en) 2021-05-18
US20160009660A1 (en) 2016-01-14
US10314840B2 (en) 2019-06-11
US20190358228A1 (en) 2019-11-28
JP2010285441A (ja) 2010-12-24
CA2474277A1 (en) 2003-08-07
US9162989B2 (en) 2015-10-20
US20050038243A1 (en) 2005-02-17
US7550460B2 (en) 2009-06-23
US20070293524A1 (en) 2007-12-20
EP1471915B1 (en) 2011-09-14
CN102174024B (zh) 2015-02-11
RS20120098A1 (sr) 2012-08-31
ATE524184T1 (de) 2011-09-15
US20040029902A1 (en) 2004-02-12
AU2008252053A1 (en) 2009-01-08
US20200085820A1 (en) 2020-03-19
RS53367B (sr) 2014-10-31
US7435814B2 (en) 2008-10-14
US20090171086A1 (en) 2009-07-02
US20150126504A1 (en) 2015-05-07
SI1471915T1 (sl) 2012-03-30
US7498435B2 (en) 2009-03-03
US20090171085A1 (en) 2009-07-02
CN1625400A (zh) 2005-06-08
US8334296B2 (en) 2012-12-18
US20070225321A1 (en) 2007-09-27
US7332484B2 (en) 2008-02-19
US7329672B2 (en) 2008-02-12
TWI329105B (en) 2010-08-21
MXPA04007386A (es) 2006-04-27
BRPI0307355B8 (pt) 2019-08-06
US8410266B2 (en) 2013-04-02
US7906644B2 (en) 2011-03-15
US20140330007A1 (en) 2014-11-06
US7642351B2 (en) 2010-01-05
AU2003208931B2 (en) 2008-09-04
US20190255047A1 (en) 2019-08-22
US9499493B2 (en) 2016-11-22
WO2003063794A2 (en) 2003-08-07
EP2281563A1 (en) 2011-02-09
US20080039622A1 (en) 2008-02-14
US20150158823A1 (en) 2015-06-11
ES2440283T3 (es) 2014-01-28
EP1471915A2 (en) 2004-11-03
US20070293523A1 (en) 2007-12-20
PT2281563E (pt) 2013-12-09
US7557210B2 (en) 2009-07-07
US9346765B2 (en) 2016-05-24
US7655797B2 (en) 2010-02-02
US7820819B2 (en) 2010-10-26
US9586908B2 (en) 2017-03-07
US20170151239A1 (en) 2017-06-01
US10828301B2 (en) 2020-11-10
US20070293522A1 (en) 2007-12-20
US9040550B2 (en) 2015-05-26
US8148525B2 (en) 2012-04-03
DK1471915T3 (da) 2012-01-09
US10682350B2 (en) 2020-06-16
US20060025410A1 (en) 2006-02-02
US10709703B2 (en) 2020-07-14
IL221381A0 (en) 2012-09-24
US20150266828A1 (en) 2015-09-24
IL221381A (en) 2015-05-31
US20110144330A1 (en) 2011-06-16
PT1471915E (pt) 2011-12-26
US20170246167A1 (en) 2017-08-31
SG167664A1 (en) 2011-01-28

Similar Documents

Publication Publication Date Title
ES2373646T3 (es) Compuestos de 2,4-pirimidindiamina y sus aplicaciones.
PT2144899E (pt) Composto epoxi e método para o seu fabrico
RU2343148C2 (ru) Соединения 2,4-пиримидиндиаминов и их применение